The Pharmaceutical Industry has always been resilient to hiring cycles. Unlike the IT Industry, there has never been a dearth of jobs in the Pharma sector. However, recruitment was steady, incremental, and stable enough to make careers long and fulfilling. Both MNC and Indian majors have enjoyed lengthy tenures from their talent. Pharmaceutical majors have also provided the right career progression opportunities for their talented individuals. Top talent in this industry has grown not only through large assignments in India but also through meaningful international opportunities. Needless to say, recruitment in the Pharmaceutical industry was done with a sense of long-term purpose.
Success Factors
Several key factors have contributed to the career growth of pharmaceutical professionals. The number of specialized hospitals in Tier 1 and 2 cities has increased. Hospitals have been corporatized, and the flow of Venture Capital into the healthcare sector has increased as well. Higher Insurance penetration in the Healthcare sector has also been a boon for the pharmaceutical industry. The International growth of Indian Pharmaceutical majors over the last 2 decades has also added sheen to the careers of Indian Pharma Professionals.
All this has meant more investment in expansion, which resulted in new plants, more R&D centers, and geographic expansions. Henceforth, talent addition has been a constant factor. People grew from within, and more people have been attracted to the Industry from outside. First came the global and domestic growth of companies like Sun, Cadila, Cipla, Lupin, Glenmark, DRL, Aurobindo, and Biocon, to name a few. Then, the global MNCs began setting up their Global In-House Centres in India. Novartis, Paraxel, AstraZeneca, Novo Nordisk & Eli Lilly are some of these many marquee names. Both these factors contributed to a steady recruitment in the Pharmaceutical Industry for the last 2 decades.
How 2025 is Forcing Pharma to Rethink Profitability
2025 hasn’t been a breeze for the Indian pharmaceutical sector either. Hiring continues to be sluggish, with many companies hitting pause on expansion plans. Global-facing Indian pharma giants are still grappling with pricing and regulatory pressures in the North American market, which is historically their most profitable territory.
On the domestic front, price controls now affect nearly a quarter of listed drugs, and the government’s scrutiny of trade margins and distribution channels has only intensified. The sharp price cap on high-margin products like cardiac stents, some slashed by as much as 80%, has reshaped profitability assumptions. These changes are disrupting long-standing business models and forcing companies to rethink their go-to-market strategies.
EBITDA margins, which were once comfortably above 25%, are under pressure. Pharma firms now face a dual challenge: sustaining their lobbying efforts to protect revenue while simultaneously innovating their operating models to safeguard margins. The impact is visible: cautious capital expenditure, reduced hiring budgets, and a tilt toward digital transformation over manpower expansion.
In essence, the pharma industry in 2025 is at a crossroads, battling regulatory headwinds, margin compression, and a war for operational efficiency.
Recruitment Realities
Pharma companies have never been the kind to hire thousands of people overnight unless a new plant or major project was on the horizon. That said, recruitment at the big players in the Pharmaceutical industry was always steady and purposeful. The top 10 Indian pharma companies, for instance, had dedicated in-house recruitment teams working around the clock. Hiring wasn’t just about replacing exits; it was about fueling growth. With every new business milestone came fresh hiring mandates.
But things are changing.
Today, the pressure on operating margins and the slowdown in R&D investments are reshaping hiring patterns. While you might still spot plenty of job openings across various pharma skill sets, a closer look reveals the truth: almost all of it is replacement hiring. Over the last two quarters, there’s been very little movement when it comes to new or expansion roles.
Make no mistake, pharma recruiters are still busy, especially when it comes to their sales teams. The top pharmaceutical companies in India each have a field force of between 7,000 and 10,000 people. These roles are associated with high attrition, and keeping them filled is a constant challenge. On average, each company hires around 200–300 sales reps every single month. This kind of hiring has always been “evergreen.”
What stands out, however, is what’s missing: the growth hiring that once powered R&D labs and new business lines. That’s the part that’s slowed down. Adding to the challenge, senior professionals in the industry are becoming cautious about switching roles, especially given the uncertain market environment and tighter business outlook.
In short, while the pharma hiring engine is still running, it’s no longer in growth mode. It’s mostly about keeping the wheels turning, not pushing new boundaries.
What’s Next? Pharma’s Route Back to Growth
In the long run, stock market pundits say Pharma still has more tailwinds in its favor. However, pharma companies have to discover their winning ways of overcoming challenges related to the US market. The US regulatory pressure is something they have weathered in the past. The larger challenge lies at home, where the pricing regulation has squeezed operating margins. They need to find a new operating model that can feed their profitability and growth. The recruitment upside will come from that. Till that time, new job creation and related recruitment frenzy will have to wait. From a hiring point of view, the Pharma Industry needs a new prescription for the good times to return in the near term.
